# Study of Immunotherapy (Sasanlimab) in Combination With Targeted Therapies in People With Advanced Non-small Cell Lung Cancer (NSCLC) (Landscape 1011 Study)

> **NCT04585815** · PHASE1,PHASE2 · TERMINATED · sponsor: **Pfizer** · enrollment: 34 (actual)

## Conditions studied

- Carcinoma, Non-Small-Cell Lung

## Interventions

- **DRUG:** Sasanlimab Prefilled syringe
- **DRUG:** Encorafenib
- **DRUG:** Binimetinib
- **DRUG:** Sasanlimab
- **DRUG:** Axitinib
- **DRUG:** SEA-TGT

## Key facts

- **NCT ID:** NCT04585815
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-11-10
- **Primary completion:** 2023-05-17
- **Final completion:** 2024-10-29
- **Target enrollment:** 34 (ACTUAL)
- **Why stopped:** Study was terminated due to portfolio re-prioritization and strategic considerations. The decision was not based on any safety concerns and/or regulatory interactions
- **Last updated:** 2026-01-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04585815

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04585815, "Study of Immunotherapy (Sasanlimab) in Combination With Targeted Therapies in People With Advanced Non-small Cell Lung Cancer (NSCLC) (Landscape 1011 Study)". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT04585815. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*